Research graph
References from FDG-PET in Cognitive Impairment and Dementia. Local targets link to admitted publications; unresolved targets remain external evidence.
Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019
10.1016/s2468-2667(21)00249-8 · 2022 · External reference
Neuropathological stageing of Alzheimer-related changes
10.1007/bf00308809 · 1991 · External reference
The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics
10.1126/science.1072994 · 2002 · External reference
Neuroinflammation in Alzheimer’s disease
10.1016/s1474-4422(15)70016-5 · 2015 · External reference
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
10.1016/s0140-6736(24)01296-0 · 2024 · External reference
Clinical and psychometric distinction of frontotemporal and Alzheimer dementias
10.1001/archneur.64.4.535 · 2007 · External reference
Dementia with Lewy bodies: definition, diagnosis, and pathogenic relationship to Alzheimer’s disease
2007 · External reference
Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report
10.1093/brain/awz099 · 2019 · External reference
In vivo FDG-PET metabolic signature of limbic-predominant age-related TDP-43 encephalopathy neuropathologic change
2023 · External reference
Co-occurrence of different pathologies in dementia: implications for dementia diagnosis
10.3233/jad-2012-111400 · 2012 · External reference
Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the NIA-AA workgroups
10.1016/j.jalz.2011.03.003 · 2011 · External reference
NIA-AA research framework: toward a biological definition of Alzheimer’s disease
10.1016/j.jalz.2018.02.018 · 2018 · External reference
Biomarker changes during 20 years preceding Alzheimer’s disease
10.1056/nejmoa2310168 · 2024 · External reference
Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup
10.1002/alz.13859 · 2024 · External reference
Clinical diagnosis of Alzheimer’s disease: recommendations of the International Working Group
10.1016/s1474-4422(21)00066-1 · 2021 · External reference
Alzheimer disease as a clinical-biological construct—an International Working Group recommendation
10.1001/jamaneurol.2024.3770 · 2024 · External reference
Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome
10.1001/jama.286.17.2120 · 2001 · External reference
Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluation
2004 · External reference
Diagnostic accuracy of amyloid versus 18F-fluorodeoxyglucose positron emission tomography in autopsy-confirmed dementia
10.1002/ana.25968 · 2021 · External reference
18F-FDG PET imaging in neurodegenerative dementing disorders: insights into subtype classification, emerging disease categories, and mixed dementia with copathologies
10.2967/jnumed.121.263194 · 2022 · External reference
Functional imaging in Alzheimer’s disease: a systematic review and meta-analysis of ASL-MRI and FDG-PET
10.1111/jon.70080 · 2025 · External reference
Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease
10.1002/ana.410420114 · 1997 · External reference
The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the NIA-AA workgroups
10.1016/j.jalz.2011.03.008 · 2011 · External reference
Value of FDG-PET scans of non-demented patients in predicting rates of future cognitive and functional decline
10.1007/s00259-017-3634-3 · 2017 · External reference
Comparison between early-onset and late-onset Alzheimer’s disease patients with amnestic presentation: CSF and 18F-FDG PET study
10.1159/000441776 · 2016 · External reference
Dementia with Lewy bodies: basis of cingulate island sign
10.1212/wnl.0000000000000734 · 2014 · External reference
A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET
2001 · External reference
FDG PET metabolic signatures distinguishing prodromal DLB from prodromal AD
2021 · External reference
FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer’s disease
10.1093/brain/awm177 · 2007 · External reference
18F-FDG PET findings in frontotemporal dementia: an SPM analysis of 29 patients
2005 · External reference
Brain imaging evidence of preclinical Alzheimer’s disease in normal aging
10.1002/ana.20799 · 2006 · External reference
Molecular imaging for predicting conversion from mild cognitive impairment to dementia: an updated systematic review
10.1007/s00259-024-06631-y · 2024 · External reference
Association of premorbid intellectual function with cerebral metabolism in Alzheimer’s disease: implications for the cognitive reserve hypothesis
10.1176/ajp.154.2.165 · 1997 · External reference
Biological and clinical heterogeneity of amnestic mild cognitive impairment revealed by FDG-PET metabolic subtypes
2023 · External reference
FDG-PET metabolic phenotypes of amnestic MCI: implications for prognosis and clinical trial design
2024 · External reference
Diagnostic performance of deep learning-assisted [18F]FDG PET imaging for Alzheimer’s disease: a systematic review and meta-analysis
10.1007/s00259-025-07228-9 · 2025 · External reference
A 3D deep learning model to predict the diagnosis of dementia with lewy bodies, Alzheimer’s disease, and mild cognitive impairment using brain 18F-FDG PET
10.1007/s00259-021-05483-0 · 2022 · External reference
EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3
10.1007/s00259-021-05603-w · 2022 · External reference
European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders
10.1016/s1474-4422(23)00447-7 · 2024 · External reference
SNMMI/EANM practice guideline for brain FDG PET, version 2.0
2024 · External reference
Brain imaging in Alzheimer disease
10.1101/cshperspect.a006213 · 2012 · External reference
Racial and ethnic differences in amyloid PET positivity in individuals with mild cognitive impairment or dementia: a secondary analysis of the IDEAS study
10.1001/jamaneurol.2022.3157 · 2022 · External reference
Clinical amyloid imaging
10.1053/j.semnuclmed.2016.09.005 · 2017 · External reference
Amyloid-β deposition and regional grey matter atrophy rates in dementia with lewy bodies
10.1093/brain/aww193 · 2016 · External reference
Cerebrospinal fluid Aβ42 levels: when physiological become pathological state
10.1111/cns.12476 · 2015 · External reference
Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia
10.1001/jama.2019.2000 · 2019 · External reference
Amyloid PET and subsequent health care use among Medicare beneficiaries with mild cognitive impairment or dementia (IDEAS study, aim 2)
10.1001/jamaneurol.2023.3490 · 2023 · External reference
New IDEAS study: amyloid PET in a racially and ethnically diverse population
10.1002/alz.70504 · 2025 · External reference
Unresolved reference
External reference
Updated appropriate use criteria for amyloid and tau PET
10.1002/alz.14338 · 2025 · External reference
A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases
10.1038/s43587-023-00471-5 · 2023 · External reference
Blood biomarkers to detect Alzheimer disease in primary care and secondary care
10.1001/jama.2024.13855 · 2024 · External reference
Highly accurate blood test for Alzheimer’s disease is similar or superior to clinical cerebrospinal fluid tests
10.1038/s41591-024-02869-z · 2024 · External reference
Relationship between atrophy and β-amyloid deposition in Alzheimer disease
10.1002/ana.21955 · 2010 · External reference
Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease
10.1093/brain/awl178 · 2006 · External reference
FDG PET for monitoring immunotherapy in Alzheimer’s disease
10.3390/diagnostics13132254 · 2023 · External reference
Lecanemab in early Alzheimer’s disease
10.1056/nejmoa2212948 · 2023 · External reference
Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial
10.1001/jama.2023.13239 · 2023 · External reference
Three dimensions of the amyloid hypothesis: time, space and “wingmen.”
10.1038/nn.4018 · 2015 · External reference
An expanded role for neuroimaging in the evaluation of memory impairment
10.3174/ajnr.a3644 · 2013 · External reference
Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease
10.1093/brain/awx243 · 2017 · External reference
Tau pathology is associated with synaptic density and longitudinal synaptic loss in Alzheimer’s disease
2024 · External reference
Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease
10.1001/jamaneurol.2021.1858 · 2021 · External reference
Amyloid- and tau-PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline
10.1038/s41591-022-02049-x · 2022 · External reference
Tau PET positivity varies with age, amyloid status, APOE genotype, and sex across the Alzheimer’s disease spectrum
10.1038/s41593-025-02000-6 · 2025 · External reference
Biomarker modeling of Alzheimer’s disease using PET-based Braak staging
10.1038/s43587-022-00204-0 · 2022 · External reference
Comparison of tau-PET tracers for in vivo Braak staging: the HEAD study
2024 · External reference
Direct comparison of the tau PET tracers [18F]flortaucipir and [18F]MK-6240 in human subjects
10.2967/jnumed.120.254961 · 2022 · External reference
Antemortem differential diagnosis of dementia pathology using structural MRI: differential–STAND
10.1016/j.neuroimage.2010.12.073 · 2011 · External reference
Multimodal deep learning for Alzheimer’s disease dementia assessment
10.1038/s41467-022-31037-5 · 2022 · External reference
A deep learning MRI approach outperforms other biomarkers of prodromal Alzheimer’s disease
10.1186/s13195-022-00985-x · 2022 · External reference
Amyloid-related imaging abnormalities with emerging Alzheimer disease therapeutics: detection and reporting recommendations for clinical practice
10.3174/ajnr.a7586 · 2022 · External reference
Lecanemab: appropriate use recommendations
10.14283/jpad.2023.30 · 2023 · External reference
ARIA monitoring in clinical practice: updated considerations for anti-amyloid immunotherapy
10.3174/ajnr.a8469 · 2025 · External reference
Optimizing use of neuroimaging tools in evaluation of Alzheimer’s disease and related dementias
10.3233/jad-200487 · 2020 · External reference
Recommendations for the diagnosis and management of Alzheimer’s disease and other disorders associated with dementia: EFNS guideline
10.1111/j.1468-1331.2006.01605.x · 2007 · External reference
EFNS guidelines for the diagnosis and management of Alzheimer’s disease
10.1111/j.1468-1331.2010.03040.x · 2010 · External reference
Practical use of DAT SPECT in diagnosing dementia with Lewy bodies: a US perspective
10.3389/fneur.2024.1395413 · 2024 · External reference
The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET
10.1016/j.jalz.2014.07.003 · 2015 · External reference
CenTauR: toward a universal scale and masks for standardizing tau imaging studies
2023 · External reference
